Control of acute emesis in repeated courses of moderately emetogenic chemotherapy

Journal of B.U.ON.

Volumn 7, Issue 1, 2002, Pages 57-60

  Raynov, Julian ^a   Danon, S ^a   Valerianova, Z ^a  

^a MILITARY MEDICAL ACADEMY   (Bulgaria)

Author keywords

Antiemetics; Corticosteroids; Cyclophosphamide; Metoclopramide; Moderately emetogenic chemotherapy; Ondansetron

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; LAXATIVE; METHYLPREDNISOLONE; METOCLOPRAMIDE; MITOXANTRONE; ONDANSETRON; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE;

ACUTE DISEASE; ADULT; AGE; ANTIEMETIC ACTIVITY; ARTICLE; BREAST CANCER; CALCULATION; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE CONTROL; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; FEMALE; HEADACHE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONHODGKIN LYMPHOMA;

EID: 0036243341     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Proposal for classifying the acute emetogenicity of cancer chemotherapy
2. Treatment of chemotherapy-induced emesis
3. Antiemetic therapy
4. Controle optimale par l'ondansetron des nausees et vomissement aigus et prolonges dans les chimiotherapies ne comportant pas de cisplatine
5. Management of other non-cisplatin-induced emesis
6. Optimal control of cyclophosphamide-induced emesis
7. Prevention of chemotherapy and radiotherapy-induced emesis: Results of the Perugia Consensus Conference
8. Guidelines for antiemetic therapy: Acute emesis
9. Recommendation for the use of antiemetics: Evidence-based clinical practice guidelines
10. Antiemetic control in cancer patients treated with highly emetogenic chemotherapy
11. Improvement in the control of chemotherapy-induced emesis with ondansetron, methylprednisolone and lorazepam combination in patients treated by a moderate emetic chemotherapy and uncontrolled by a previous antiemetic combination
12. A comparative study of Granisetron i.v. versus ondansetron i.v./oral in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy
13. 3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy. A randomized study
14. Comparative trial of oral granisetron and intravenous ondansetron in patients receiving chemotherapy for breast cancer. Study group of Granisetron
15. Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide induced emesis in cancer patients: A multicenter, double-masked study. Ondansetron Orally Disintegrating Tablet Emesis Study Group
16. Antiemetic efficacy of single-dose oral granisetron (1 mg vs 2 mg) in patients with moderately emetogenic chemotherapy
17. Tropisetron: An update of its use in the prevention of chemotherapy-induced nausea and vomiting
18. Effectiveness of oral 5-HT3 receptor antagonists for emetogenic chemotherapy
19. Oral granisetron for the prevention of acute late onset nausea and vomiting in patients treated with moderately emetogenic chemotherapy
20. A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy
21. The impact of the antiemetic therapy on the quality of life (QOL) in cancer patients
22. Management of cyclophosphamide-induced emesis over repeat courses
23. Progressive loss of antiemetic efficacy during subsequent courses of chemotherapy
24. The role of ondansetron in the prevention of non-cisplatin induced vomiting: A randomized trial
25. Comparison of ondansetron with metoclopramide in the control of emesis induced by moderately emetogenic chemotherapy used for lymphoma and leukemia patients
26. Chemotherapy-induced emesis: Management of early and delayed emesis in milder emetogenic regimens
27. Antiemetic efficacy of ondansetron and metoclopramide, both combined with corticosteroids, in malignant lymphoma patients receiving non-cisplatin chemotherapy